Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis Sells 2,449 Shares

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 2,449 shares of the company's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the sale, the chief financial officer owned 103,569 shares of the company's stock, valued at $3,951,157.35. This trade represents a 2.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Adam Laponis also recently made the following trade(s):

• On Wednesday, May 21st, Adam Laponis sold 936 shares of Twist Bioscience stock. The stock was sold at an average price of $29.75, for a total value of $27,846.00.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST traded down $0.44 during trading on Friday, hitting $38.03. The stock had a trading volume of 679,091 shares, compared to its average volume of 969,730. Twist Bioscience Corporation has a 12-month low of $27.12 and a 12-month high of $60.90. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -11.70 and a beta of 2.41. The company has a quick ratio of 4.24, a current ratio of 4.51 and a debt-to-equity ratio of 0.03. The stock has a 50-day simple moving average of $33.38 and a two-hundred day simple moving average of $39.98.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 33.48% and a negative net margin of 54.98%. The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. On average, equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Arizona State Retirement System grew its holdings in Twist Bioscience by 1.3% during the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after acquiring an additional 219 shares during the period. Hillsdale Investment Management Inc. grew its holdings in Twist Bioscience by 0.4% in the fourth quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock valued at $3,625,000 after purchasing an additional 300 shares during the period. GAMMA Investing LLC grew its holdings in Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after purchasing an additional 303 shares during the period. Deerfield Management Company L.P. Series C grew its holdings in Twist Bioscience by 1.7% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 23,827 shares of the company's stock valued at $1,107,000 after purchasing an additional 403 shares during the period. Finally, Summit Investment Advisors Inc. grew its holdings in Twist Bioscience by 7.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock valued at $283,000 after purchasing an additional 443 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. decreased their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Guggenheim restated a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research note on Tuesday, May 6th. Robert W. Baird decreased their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays decreased their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.